Loading…
Slendid sold unapproved and misbranded compounded semaglutide and tirzepatide products to U.S. consumers through its website, violating the Federal Food, Drug, and Cosmetic Act. The company falsely claimed its compounded drugs were "clinically proven weight loss treatments," implying they were equivalent to FDA-approved products when compounded drugs lack FDA approval. This misleading advertising of compounded drugs violated sections 502(a) and 502(bb) of the FDCA, constituting prohibited introduction of misbranded products into interstate commerce under section 301(a).